CClinicalTrials.gg
CompletedNCT06937775Updated Jul 24, 2025

Rapid Maxillary Expansion Related Oxidative Stress and Periodontal Results

An interventional study of Periodontal measurements (plaque index, gingival index and probing pocket depth scores ) and Biochemical Sample Supply (Collection of serum and saliva samples) in Maxillary Expansion, sponsored by Recep Tayyip Erdogan University Training and Research Hospital. Completed. Open to participants aged 11 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Recep Tayyip Erdogan University Training and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 years 2 months after the study started (first participant enrolled Jan 2016, registered Mar 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
11 Years to 16 Years
Sex
All
01

Study summary

The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Serum and saliva samples will be collected from each patient during four different periods: a week before the treatment (T0), on the day of sutural separation (T1), at the end of the active expansion period (T2), and after the completion of a 3-month retention period (T3). To evaluate the patients' periodontal status, plaque index, gingival index, and probing pocket depth scores will be recorded for each period. 8-hydroxydeoxyguanosine (8-OHdG), total oxidative status (TOS), total antioxidant capacity (TAS), and oxidative stress index (OSI) biomarkers will be evaluated to determine the local and systemic oxidative stress levels.

02

Conditions studied

  • Maxillary Expansion
03

In context

Lead sponsor

Recep Tayyip Erdogan University Training and Research Hospital is the lead sponsor of 85 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Being between 11-15 years of age,
  • Having an indication for maxillary expansion due to maxillary stenosis,
  • Being highly cooperative, performing adequate oral care,
  • Being periodontally healthy,
  • Not having cleft lip and/or palate anomalies,
  • Not having any systemic disease,
  • Not having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Not being substance addicted and not smoking.

Exclusion criteria

Exclusion Criteria:

  • Having inadequate oral hygiene
  • Being periodontally unhealthy
  • Having cleft lip and/or palate anomalies,
  • Having any systemic disease,
  • Having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Being substance addicted and not smoking.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Other
    TO

    1 week before the placement of the Hyrax appliance

    Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ) · Other: Biochemical Sample Supply (Collection of serum and saliva samples)

  • Other
    T1

    The day of the first clinical observation of sutural opening (5-7 days after activation)

    Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ) · Other: Biochemical Sample Supply (Collection of serum and saliva samples) · Procedure: Rapid maxillary expansion with Hyrax appliance

  • Other
    T2

    The day of completion of active expansion (3-4 weeks)

    Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ) · Other: Biochemical Sample Supply (Collection of serum and saliva samples) · Procedure: Rapid maxillary expansion with Hyrax appliance

  • Other
    T3

    The day of completion of the 3-month reinforcement period

    Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ) · Other: Biochemical Sample Supply (Collection of serum and saliva samples) · Procedure: Rapid maxillary expansion with Hyrax appliance

Interventions

  • OtherPeriodontal measurements (plaque index, gingival index and probing pocket depth scores )

    Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.

  • OtherBiochemical Sample Supply (Collection of serum and saliva samples)

    Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses. For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day. Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes.

  • ProcedureRapid maxillary expansion with Hyrax appliance

    Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.

06

What researchers measure

Primary outcomes

  1. Biochemical analyses - 8-OHdG

    8-OHdG is the most frequently encountered and best known mutagenicity of more than 20 oxidative base damage products of ROS in DNA. Since it is easily detected in living cells and body fluids, it is the most commonly used oxidative DNA damage marker. Serum and saliva levels will be measured using a suitable ELISA kit (Cayman Chemical DNA/RNA Oxidative Damage ELISA Kit Item No.589320) according to the manufacturer's instructions. The measurement principle is as follows: It is based on the competition between 8-OHdG from the sample and 8-OHdG-acetylcholinestarase conjugate (8- OHdG Tracer) from the kit for a limited amount of 8-OHdG monoclonal antibody covering the plate well. The colour intensity measured spectrophotometrically at 410 nm is directly proportional to the tracer and inversely proportional to the amount of free 8-OHdG in the sample.

    Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  2. Biochemical analyses - Oxidative Stress Index (TOS/TAS=OSI)

    Total Oxidative Status (TOS) is a current method used to detect lipid peroxidation and oxidative stress. TOS is considered to be a superior method compared to other methods due to the impracticality of measuring different oxidant molecules individually and the inability to fully reflect the interaction of oxidant molecules with each other. Total Antioxidan Status (TAS) is a biochemical parameter obtained as a result of the sum of the antioxidant capacities of all antioxidants in the biological samples examined. Oxidative Stress Index (OSI) is a proportional value obtained by dividing TOS by TAS. It is directly affected by total oxidative and antioxidant status and reveals the final oxidative status in a practical and understandable way. OSI value was calculated according to the following formula. OSI = TOS (mmol H2O2 Equiv./L) / TAS (mmol Trolox Equiv./L) x 100

    Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

Secondary outcomes

  1. Clinical Periodontal Assessments-plaque index

    Plaque index (PI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. The amount and thickness of plaque causing gingival inflammation will be determined. The teeth will be dried by spraying light air and isolated. Each tooth will be scored by measuring with a probe from the gingival margin in six areas (mesiobuccal, distobuccal, mesial, distal, oral, vestibule).

    Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  2. Clinical Periodontal Assessments-gingival index

    Gingival index (GI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status of the participants. The periodontal probe will be placed in the gingival sulcus parallel to the long axis of the teeth from the gum edge. Measurements will be made from the area under the teeth and scoring will be done according to the surface characteristics of the gum. The value found will be divided by the number of teeth and the gingival index will be determined for the entire mouth.

    Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  3. Clinical Periodontal Assessments-probed pocket depth (PPD)

    PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.

    Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06937775
Lead sponsor
Recep Tayyip Erdogan University Training and Research Hospital
Responsible party
Dilek KARADOĞAN (Assoc. Prof. Dr., Recep Tayyip Erdogan University Training and Research Hospital) — Principal investigator
First posted
Apr 22, 2025
Start date
Jan 10, 2016
Primary completion
Mar 10, 2016
Completion
Aug 10, 2016
Last update
Jul 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion